Progyny Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
38.0%projected annual EPS growth
Analyst Coverage
11analysts covering
FY Revenue (est.)
$1.4Bnext fiscal year
FY EPS (est.)
$2.08next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
| Q4 and Full Year 2026 Earnings Release | 25 Feb 2027 |
Monitoring Framework
Key Performance Indicators
Covered Lives Quarterly7.2M
Number of Clients Quarterly595Target: Over 600
Net Promoter Score (NPS) - Fertility Benefits Annually81.0
Net Promoter Score (NPS) - Progyny Rx Annually79.0
Watch Items
- Employer Benefit Budget TighteningTrigger: Slowing of new client wins or reduction in covered lives during the selling seasonAction: Re-evaluate revenue growth projections and adjust sales strategy to target smaller employers via Progyny Select
- Progyny Rx Economics and PBM Pricing PressureTrigger: Compression of pharmacy benefit margins or loss of key pharmacy network partnershipsAction: Assess contract terms with pharmacy benefit managers and explore alternative pricing structures
- Competitive Intensity and Pricing PressureTrigger: Competitors matching comprehensive offerings or offering lower-cost cash-pay alternativesAction: Enhance clinical outcomes differentiation and expand newer solutions like menopause and midlife care
Research as of 20 Jun 2026